An audit of corporate decarbonisation ambition against low carbon futures. [PDF]
Weaver I +5 more
europepmc +1 more source
K562に対する血小板細胞傷害性におけるプロテアーゼインヒビターの効果
K-562に対する血小板細胞傷害性におけるプロテアーゼインヒビターの効果を調べた。 Soybean trypsin inhibitor(SBTI), N-p-tosyl-L-phenylalanine chloromethyl ketone(TPCK), アプロニチン、ペプスタチンは未処理血小板によるK-562の細胞変形を効果的に阻害したが、N-p-tosyl-L-lysine chloromethyl ketone(TLCK)とロイペプチンは阻害しなかった。SBTI、アプロチニン ...
トミナガ, アキオ +23 more
core +1 more source
SPINK3-Sperm Interaction Determines a Stable Sperm Subpopulation With Intact CatSper Channel. [PDF]
Nicolli AR +10 more
europepmc +1 more source
SrBi4Ti4O15 (SBTi) thin films were prepared on (100)- and (110)-oriented LaNiO3(LNO) electrodes by a metalorgranic decomposition (MOD) technique at an annealing temperature of 650°C.
SUHUA FAN +3 more
core
持續排放責任的履行方案:SBTi 企業淨零標準 V2.0 之 OER 制度解析與台灣情境
本報告解析 SBTi 企業淨零標準 2.0 版(2026 年 6 月發布)新增之持續排放責任(Ongoing Emissions Responsibility, OER)制度,逐條對照標準原文,量化其成本結構,並檢視對台灣企業的影響。 三項發現與主流評論不同。其一,OER 認可制度並不要求碳移除:合格之已驗證減量成果包含價值鏈外減量與自然碳匯復育,貢獻預算亦得用於研究、調適或損失與損害;強制移除僅出現於 2035 年後要求(C45)與淨零中和(C46)。其二,C45.4 之長效移除配額分母為「可歸因於長效溫室氣體之受涵蓋排放」,而非持續排放總量;與C45.1 所定 1% 涵蓋比例相乘後,2035 年之最低長效移除義務較普遍引述之數字小約三個數量級,其後則因兩條線性斜坡相乘而呈二次成長。其三,C43.
openaire +2 more sources
Soybean Trypsin Inhibitor Possesses Potency Against SARS-CoV-2 Infection by Blocking the Host Cell Surface Receptors ACE2, TMPRSS2, and CD147. [PDF]
Wu WL +5 more
europepmc +1 more source
Can Science-Based Targets Make the Private Sector Paris-Aligned? A Review of the Emerging Evidence. [PDF]
Bjørn A, Tilsted JP, Addas A, Lloyd SM.
europepmc +1 more source
Controlling Cellular Behavior by Surface Design of Titanium-based Biomaterials. [PDF]
Andreeva T +6 more
europepmc +1 more source
Adopting science based targets – effects on mitigating freight transport emissions
An increasing number of corporations have adopted voluntary climate targets and seek verification of their ambitions through multi-stakeholder initiatives (MSIs).
Gustavsson Binder, Tobias, +2 more
core
Accountability, ambition, and quantifiable action in the carbon emission reduction plans of the ten largest pharmaceutical companies in Australia: a cross-sectional analysis. [PDF]
Burch H +4 more
europepmc +1 more source

